GY036 for stage 3/4 gynecologic cancers with pathogenic BRCA 1/2 mutation or HR deficiency

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
NRG-GY036, A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NCT#06580314)
Principal Investigator
Headshot of Angeles Alvarez Secord
Professor of Obstetrics and Gynecology
Protocol Number
IRB: PRO00117512
NCT: NCT06580314
Phase
Phase III
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL